AbbVie’s $10.1 billion purchase of ImmunoGen and accompanying antibody-drug conjugate Elahere is already paying off, with the drug scoring a new mid-stage victory.
The Chicago …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AUXLY ANNOUNCES COMPLETION OF CONVERSION OF OVER $123 MILLION OF PRINCIPAL AND INTEREST UNDER IMPERIAL DEBENTURE Imperial Brands plc converts over $123 million in total
Rheumatologist Jason Liebowitz, MD, was “really enjoying” his job at a physician-owned practice when, about a year in, it was acquired by a private equity
EyeBio’s tri-specific Wnt agonist antibody improved visual and anatomical measures in a Phase Ib/IIa trial as a monotherapy and in combination with Regeneron’s Eylea, prompting